Toby N Weingarten1, Elisa Y Chong2, Darrell R Schroeder3, Juraj Sprung4. 1. Department of Anesthesiology, Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA. weingarten.toby@mayo.edu. 2. Mayo Clinic Medical Student, Mayo Clinic College of Medicine, Mayo Medical School, Mayo Clinic, Rochester, MN, USA. 3. Mayo Clinic College of Medicine, Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 4. Department of Anesthesiology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE: To identify characteristics associated with postoperative respiratory depression that required naloxone intervention during Phase I recovery following general anesthesia. A secondary aim is to compare postoperative outcomes between patients who received naloxone and those who did not. METHODS: Patients who received naloxone to reverse opioid-induced respiratory depression or sedation during Phase I postanesthesia recovery from January 1, 2010 to December 31, 2013 were identified and matched to 2 controls based on age, sex, and surgical procedure during the same year. A chart review was performed to identify factors associated with risk for intervention requiring naloxone as well as to note the occurrence of adverse postoperative outcomes. Analyses to assess characteristics potentially associated with naloxone use were performed using conditional logistic regression taking into account the 1:2 matched set case-control study design. RESULTS: Naloxone was administered to 413 patients, with an incidence of 2.5 per 1000 anesthetics [95 % confidence interval (CI) 0.7-6.5]. Presence of obstructive sleep apnea [odds ratio (OR) = 1.74, 95 % CI 1.22-2.48, P = 0.002], ASA Physical Status (PS) ≥III (OR 1.44, 95 % CI 1.08-1.92, P = 0.013), and greater opioid administration (OR 1.22, 95 % CI 1.12-1.33, per 10 intravenous morphine equivalents mg, P < 0.001) were associated with naloxone administration. Naloxone administration was associated with increased adverse events (OR 3.39, 95 % CI 2.22-5.23, P < 0.001). CONCLUSIONS: Obstructive sleep apnea, higher ASA-PS scores and greater doses of intraoperative opioids were associated with naloxone administration during Phase I recovery. Patients administered naloxone had increased adverse events after discharge from the recovery room and may benefit from a higher level of postoperative care.
PURPOSE: To identify characteristics associated with postoperative respiratory depression that required naloxone intervention during Phase I recovery following general anesthesia. A secondary aim is to compare postoperative outcomes between patients who received naloxone and those who did not. METHODS:Patients who received naloxone to reverse opioid-induced respiratory depression or sedation during Phase I postanesthesia recovery from January 1, 2010 to December 31, 2013 were identified and matched to 2 controls based on age, sex, and surgical procedure during the same year. A chart review was performed to identify factors associated with risk for intervention requiring naloxone as well as to note the occurrence of adverse postoperative outcomes. Analyses to assess characteristics potentially associated with naloxone use were performed using conditional logistic regression taking into account the 1:2 matched set case-control study design. RESULTS:Naloxone was administered to 413 patients, with an incidence of 2.5 per 1000 anesthetics [95 % confidence interval (CI) 0.7-6.5]. Presence of obstructive sleep apnea [odds ratio (OR) = 1.74, 95 % CI 1.22-2.48, P = 0.002], ASA Physical Status (PS) ≥III (OR 1.44, 95 % CI 1.08-1.92, P = 0.013), and greater opioid administration (OR 1.22, 95 % CI 1.12-1.33, per 10 intravenous morphine equivalents mg, P < 0.001) were associated with naloxone administration. Naloxone administration was associated with increased adverse events (OR 3.39, 95 % CI 2.22-5.23, P < 0.001). CONCLUSIONS:Obstructive sleep apnea, higher ASA-PS scores and greater doses of intraoperative opioids were associated with naloxone administration during Phase I recovery. Patients administered naloxone had increased adverse events after discharge from the recovery room and may benefit from a higher level of postoperative care.
Authors: Toby N Weingarten; Sam J Venus; Francis X Whalen; Brittany J Lyne; Holly A Tempel; Sarah A Wilczewski; Bradly J Narr; David P Martin; Darrell R Schroeder; Juraj Sprung Journal: Mayo Clin Proc Date: 2012-01 Impact factor: 7.616
Authors: Bhargavi Gali; Francis X Whalen; Peter C Gay; Eric J Olson; Darrell R Schroeder; David J Plevak; Timothy I Morgenthaler Journal: J Clin Sleep Med Date: 2007-10-15 Impact factor: 4.062
Authors: Gary M Oderda; Qayyim Said; R Scott Evans; Gregory J Stoddard; Jim Lloyd; Kenneth Jackson; Dale Rublee; Matthew H Samore Journal: Ann Pharmacother Date: 2007-03-06 Impact factor: 3.154
Authors: Shoshana J Herzig; Mihaela S Stefan; Penelope S Pekow; Meng-Shiou Shieh; William Soares; Karthik Raghunathan; Peter K Lindenauer Journal: J Gen Intern Med Date: 2019-11-14 Impact factor: 5.128
Authors: S Chandralekha Kruthiventi; Garvan C Kane; Juraj Sprung; Toby N Weingarten; Mary Ellen Warner Journal: Bosn J Basic Med Sci Date: 2019-11-08 Impact factor: 3.363
Authors: Marek Brzezinski; Gregory B Hammer; Keith A Candiotti; Sergio D Bergese; Peter H Pan; Michael H Bourne; Cathy Michalsky; Linda Wase; Mark A Demitrack; Ashraf S Habib Journal: Pain Ther Date: 2021-01-21
Authors: Frances Chung; Jean Wong; Michael L Mestek; Kathleen H Niebel; Peter Lichtenthal Journal: J Clin Monit Comput Date: 2019-06-07 Impact factor: 2.502
Authors: Stavros G Memtsoudis; Crispiana Cozowicz; Mahesh Nagappa; Jean Wong; Girish P Joshi; David T Wong; Anthony G Doufas; Meltem Yilmaz; Mark H Stein; Megan L Krajewski; Mandeep Singh; Lukas Pichler; Satya Krishna Ramachandran; Frances Chung Journal: Anesth Analg Date: 2018-10 Impact factor: 5.108
Authors: Bhargavi Gali; Sarah R Gritzner; Amy J Henderson; Mary E Warner; Sinokuthaba L Sibanda; Juraj Sprung; Toby N Weingarten Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27